September 15, 2011 Proactive Investors One2One Investor Forum

The directors of ImmunoCellular Therapeutics (OTCBB: IMUC), International Stem Cell (OTCBB: ISCO) and OncoSec Medical Incorporated (OTCBB: ONCS) will be presenting:

Thursday the 15th September 2011,
Intercontinental New York Barclay Hotel, 111 East 48th Street, New York – 3rd Floor Beekman Room I & II

The presentations will start at 6:00pm and finish at 7.30 pm. After the presentations are complete the directors will also be available to take questions during a free canape and wine reception. Details on the presenting companies can be found below.

If you have any problems registering or queries please email ed@proactiveinvestorsusa.com.

ImmunoCellular Therapeutics Company logo ImmunoCellular Therapeutics (OTCBB:IMUC)

ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. The product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat different cancers.

International Stem Cell  Company logo International Stem Cell (OTCBB:ISCO)

International Stem Cell Corporation is a biotechnology company. The Company is focused on therapeutic biomedical research and cosmeceutical products. It generates revenue and provides cell manufacturing knowledge and infrastructure to support long term therapeutic objectives.

OncoSec Medical Incorporated Company logo OncoSec Medical Incorporated (OTCBB:ONCS)

OncoSec Medical Inc. (OMI) is an advanced-stage biomedical company focused on commercializing therapeutic oncology products. Founded in 2011, the company is committed to bringing patients new and improved treatment alternatives to existing therapies that have untoward side-effects and where improvements to the patient’s treatment and personal well-being are both desirable and achievable.
For more info, click here.

The comments are closed.